Navigation Links
Sorbent Therapeutics Completes $36 Million Series B Financing for Net of $53 Million
Date:6/30/2011

heart failure, CLP1001. We believe CLP1001 has the potential to address a significant need in the cardiovascular market for safe and effective management of electrolyte and fluid levels in patients with CHF."

About CLP1001 in Heart Failure

Sorbent's lead product, CLP1001, is a polymer that has been shown to remove potassium, sodium and fluid with good tolerability in over 100 patients and healthy volunteers. The addition of CLP1001 to the treatment regimen in heart failure patients may address fluid overload and the risk of hyperkalemia related to the use of multiple RAAS (Renin-Angiotensin-Aldosterone System) blockers.

About Congestive Heart Failure

Congestive heart failure is a serious and life-threatening condition that  develops when the heart loses its ability to pump blood efficiently, allowing fluid to accumulate in the lungs, abdominal organs (especially the liver) and peripheral tissues. According to the American Heart Association, approximately 5.7 million people in the U.S. are living with heart failure, a condition that accounts for 1.1 million hospitalizations each year. Heart failure is estimated to cost the U.S. healthcare system over $37 billion annually.

About Sorbent

Sorbent Therapeutics is a private biopharmaceutical company developing therapies for patients requiring targeted cation and fluid removal from the body. The Company is focused on the development of a platform of non-absorbed polymeric drugs to satisfy unmet clinical needs in large cardiovascular and renal markets such as heart failure, end stage renal disease, chronic kidney disease and hypertension. The Company is headquartered in Sunnyvale, California. For more information, visit www.sorbent.com.


'/>"/>
SOURCE Sorbent Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Allied Healthcare Announces Litholyme(TM) -- New CO2 Absorbent Used in Anesthesia
2. Reportlinker Adds US Enzyme-Linked Immunosorbent Assay (ELISA) Industry
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Pharmaceutic Labs announces the opening of its ... NY for admixing, compounding, drug shortages and ... the FDA standards for safety and quality, using 21 ... The 10,000 square foot outsourcing facility was ... and quality control. The company will produce sterile and ...
(Date:10/19/2014)... , Oct. 20, 2014 CTI BioPharma ... it will report its third quarter 2014 financial results ... the U.S. financial markets. Following the announcement, members of ... to discuss the results and provide a general corporate ... to the event can be obtained as follows: ...
(Date:10/17/2014)... CHAPEL HILL, N.C. , Oct. 17, 2014 ... key insights is a critical success factor in ... companies must develop market research organizations that effectively ... their location, specialty or service area. ... groups create value and earn recognition from internal ...
Breaking Medicine Technology:CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2Effective Training Programs for Market Research Groups can Boost Overall Organizational Success 2
... Since Groundbreaking 2002 ... ... new study reveals that,coiling, a minimally invasive procedure to treat aneurysms ... after,initial treatment in those aneurysms considered "untouchable" by the,traditional surgical option. ...
... in Copper,s Ability to Reduce Threat of ... Improve Indoor Air Quality, NEW YORK, Aug. 1 ... and bronze have,been awarded to the Copper Development Association, announced ... on the ability of copper metals to kill deadly,pathogens on ...
Cached Medicine Technology:New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results 2New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results 3Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals 2Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals 3
(Date:10/20/2014)... 2014 Do you ever feel difficulty ... a wonderful app Metassessor for teachers, specialists and parents. ... helped its client “Intervention Development LLC” to launch Metassessor ... designed for iOS 4.3 or later and is Compatible ... optimized for iPhone 5. It is now available on ...
(Date:10/19/2014)... BambooIndustry.com, one of the most popular suppliers of bamboo ... deckings . Moreover, the company has launched a special ... at deeply discounted rates. , As is known ... significance of online business nowadays. Thus, BambooIndustry.com pays a ... are striving to deliver both value and efficiency for ...
(Date:10/19/2014)... Having been working in the garment industry for ... needs. According to James, one of the company’s top designers, ... with high-low skirts that add beauty to them. Chiffon floor ... has unveiled its new selection of 2014 long prom dresses. ... new items are available in over 20 popular designs. The ...
(Date:10/19/2014)... a professional company of women’s dresses and related accessories, ... dresses . All the company’s old and new client ... up to 66 percent off. , SweetDressy.com is ... Its dress specialists are striving to make more trendy ... world. All the company’s items are unique, graceful and ...
(Date:10/19/2014)... stem cell-based research could improve understanding of intestinal diseases ... suggests. Scientists used stem cells to grow "organoids" ... They then transplanted the organoids into mice, creating a ... researchers. "This provides a new way to study ... failure, from genetic disorders appearing at birth to conditions ...
Breaking Medicine News(10 mins):Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2Health News:Scientists Grow, Implant Human Intestinal Tissue in Mice 2
... When you check into a hospital, the odds are one ... of antibiotic-resistant bacteria as a result of your stay. That ... todays hospitals despite the best efforts of the medical profession. ... deaths per year., Now, a sophisticated new mathematical model has ...
... for,Plastination commends ABC,s 20/20 for its investigation on ... exhibitions. The program served to,inform and educate the ... of bodies used in anatomical exhibitions in particular., ... clarify two vague,statements made by anatomist, Dr. Gunther ...
... survival rates to younger cases , , FRIDAY, Feb. 15 ... transplantation and have good outcomes, and age should not ... a new study says. , Researchers at the University ... of 48 UCLA patients between the ages of 65 ...
... Canadian scientists are finding that out of sight, out of ... the chemicals in our waters. Substances that we use everyday ... they can impact aquatic life and possibly ourselves. , ... of the 30,000 or so chemicals used commercially in the ...
... Premier Exhibitions Inc.,(Nasdaq: PRXI ) today posted ... to an expected 20/20 broadcast that is purported ... to its controversial and,highly successful bodies exhibitions., ... TV,s 20/20 has,chosen to air a segment that ...
... 15 IDEXX Laboratories,Inc. (Nasdaq: IDXX ), announced ... by the Company of an additional four million,shares of ... will be made in the open market or in ... shares remaining as of,December 31, 2007, under a previous ...
Cached Medicine News:Health News:Math model identifies key to controlling epidemic 2Health News:Math model identifies key to controlling epidemic 3Health News:Specimens in BODY WORLDS Exhibitions Stem Primarily from German Body Donation Program 2Health News:Good Outcomes Possible for Older Lung Transplant Patients 2Health News:New findings on emerging contaminants 2Health News:New findings on emerging contaminants 3Health News:New findings on emerging contaminants 4Health News:New findings on emerging contaminants 5Health News:An Open Letter to 20/20 and the Shareholders of Premier Exhibitions, Inc. 2Health News:An Open Letter to 20/20 and the Shareholders of Premier Exhibitions, Inc. 3
Bivona® stylets are manufactured of malleable stainless steel wire. The length can be adjusted by sliding the attached silicone stopper. The Blue Line® tracheal tube introducer (bougie) is de...
All endotracheal accessories are designed to ensure your technique. The Blue Line® intubation stylets feature a satin-smooth coating and are available in three sizes....
All endotracheal accessories are designed to ensure your technique. The Blue Line® intubation stylets feature a satin-smooth coating and are available in three sizes....
... Aaron manufactures two groups of flexible ... sterile and non-sterile in three different sizes ... flexible shaft portion of the light). These ... additional light is needed., ,The second ...
Medicine Products: